Page 49 - Noble-Virtual-Healthcare-2024
P. 49
Tharimmune, Inc.
SELECTED FINANCIAL ITEMS THAR
(in millions of USD)
CQ1 '23 CQ2 '23 CQ3 '23 CQ4 '23 LTM
Income Statement Key Items
Total Revenue NA NA NA NA 0.00
Gross Profit NA NA NA NA 0.00
Gross Margin NM NM NM NM NM
EBIT (2.71) (2.36) (1.85) (2.53) (9.46)
EBIT Margin NM NM NM NM NM
Net Income to Common Shareholders (2.69) (2.34) (1.82) (2.47) (9.32)
Net Margin NM NM NM NM NM
Balance Sheet Key Items
Total Assets 4.72 4.60 3.17 10.95 10.95
Cash & Short Term Investments 3.57 3.90 2.69 10.94 10.94
% of Assets 76% 85% 85% 100% 100%
Current Assets -Total 4.72 4.60 3.17 10.95 10.95
% of Assets 100% 100% 100% 100% 100%
Total Liabilities 1.52 1.53 1.41 1.82 1.82
% of Assets 32% 33% 45% 17% 17%
Current Liabilities - Total 1.52 1.53 1.41 1.82 1.82
% of Assets 32% 33% 45% 17% 17%
Long Term Debt NA NA NA NA NA
% of Assets NM NM NM NM NM
Total Equity 3.20 3.07 1.76 9.13 9.13
% of Assets 68% 67% 55% 83% 83%
Cash Flow Statement Key Items
Net Cash Flow - Operating Activities (3.46) (1.51) (0.91) (1.42) (7.30)
Net Cash Flow - Investing NA NA NA NA 0.00
Net Cash Flow - Financing 0.52 1.85 (0.31) 9.66 11.72
Source: Capital IQ
PRICE / VOLUME
Source: Channelchek/QuoteMedia
Noble Capital Markets' Nineteenth Annual Small & Microcap Investor Conference